Ščudla Vlastimil, Pika Tomáš, Minařík Jiří
Vnitr Lek. 2015 Jan;61(1):60-1, 63-71.
The aim of the paper is to inform about the contribution of novel, highly sensitive analytic technique for the assessment of serum immunoglobulins (Hevylite), enabling separate quantitative assessment of heavy/light chain pairs of immunoglobulin (HLC), i. e. the monoclonal ("involved") and polyclonal ("noninvolved") isotype including their ratio (HLC-r) in monoclonal gammopathies. We particularly target the characteristics of this technique, the compari-son of its clinical contribution with standard methods used in the diagnostics, course and the detection of relapse and progression of the disease, as well as the stratification, assessment of therapeutic outcome and prognosis in monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenström´s macroglobulinemia, systemic AL-amyloidosis and some non-Hodgkin lymphomas. Present results show that in comparison with existing routinely used techniques the Hevylite method enriches clinical practice with the assessment of serum levels of "uninvolved" Ig. It enables the evaluation of the depth of "immunoparesis", and the determination of HLC-r index that is needful for the stratification of MM into "risk cohorts". It also contributes to prognostic assessment and improvement of the evaluation of the depth of therapeutic response. In MGUS individuals the HLC-r index provides information about the risk of malignant transformation. We await the results of ongoing validation studies that are expected to provide specific indications for Hevylite technique for MG in routine practice.
本文旨在介绍一种新型高灵敏度分析技术(Hevylite)对血清免疫球蛋白评估的贡献,该技术能够对免疫球蛋白重/轻链对(HLC)进行单独定量评估,即单克隆(“受累”)和多克隆(“未受累”)同种型,包括其在单克隆丙种球蛋白病中的比例(HLC-r)。我们特别关注该技术的特点,将其临床贡献与诊断中使用的标准方法进行比较,以及疾病的病程、复发和进展的检测,还有意义未明的单克隆丙种球蛋白病、多发性骨髓瘤、华氏巨球蛋白血症、系统性AL淀粉样变性和一些非霍奇金淋巴瘤的分层、治疗结果评估和预后。目前的结果表明,与现有的常规使用技术相比,Hevylite方法通过评估“未受累”Ig的血清水平丰富了临床实践。它能够评估“免疫球蛋白缺乏症”的深度,并确定HLC-r指数,这对于将MM分层为“风险队列”是必要的。它还有助于预后评估和改善对治疗反应深度的评估。在意义未明的单克隆丙种球蛋白病个体中,HLC-r指数提供了有关恶性转化风险的信息。我们期待正在进行的验证研究结果,预计这些结果将为Hevylite技术在常规实践中用于意义未明的单克隆丙种球蛋白病提供具体指征。